Prostate Cell News 8.26 July 14, 2017 | |
| |
TOP STORYSurgery for Early Prostate Cancer May Not Save Lives A major 20-year study provides evidence that prostate cancer surgery offers negligible benefits to many men with early-stage disease. [Press release from The Washington School of Medicine in St. Louis discussing online prepublication in The New England Journal of Medicine] Press Release | Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice The authors provide preclinical proof of concept for the role of a pro-inflammatory CXCL12-CXCR4/CXCR7 signaling axis in an obesity-driven mouse model of HiMyc prostate cancer. [Cancer Res] Abstract Androgen Induces G3BP2 and SUMO-Mediated p53 Nuclear Export in Prostate Cancer Scientists report that p53 is translocated to the cytoplasm by androgen-mediated induction of G3BP2, a newly described direct target gene of androgen receptor. G3BP2 induced both cell cycle progression and blocked apoptosis. [Oncogene] Abstract Researchers report a novel tumor promoter, ZBTB46, which is negatively regulated by androgen receptor signaling via microRNA-1-mediated downregulation. [Oncogene] Abstract Investigators unravel a novel mechanism for constitutive activation of NF-κB signaling pathway in the bone metastasis of prostate cancer, supporting a functional and clinical significance of epigenetic events in bone metastasis of prostate cancer. [Mol Cancer] Full Article Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer By analysing prostate cancer bone metastases using high density microarrays, scientists found a common genomic copy number loss at 6q16.1–16.2, containing the FBXL4 gene, which was confirmed in larger series of bone metastases by fluorescence in situ hybridisation. [Sci Rep] Full Article Researchers found that Tetraspanin 1 (TSPAN1) is acutely induced by androgens, and is significantly upregulated in prostate cancer relative to both normal prostate tissue and benign prostate hyperplasia. [Sci Rep] Full Article Investigators examined whether istaroxime affects cell motility and analyzed the underlying mechanism in prostate tumor cells. [Cell Physiol Biochem] Full Article Hsp70 Inhibitors Suppress Androgen Receptor Expression in LNCaP95 Prostate Cancer Cells Scientists investigated the effect of the heat shock protein 70 (Hsp70) inhibitors quercetin and VER155008 in the prostate cancer cell line LNCaP95 that expresses androgen receptor splice variant 7 (AR-V7), and explored the mechanism by which Hsp70 regulates full-length AR and AR-V7 expression. [Cancer Sci] Full Article Researchers isolated resistant to docetaxel (DCTR) clones respectively from 22Rv1 and DU-145 prostate cancer cell lines and performed through next-generation sequencing the miRNAs profiles of the released miRNAs. [Int J Mol Sci] Full Article Macrocyclic Peptides Decrease c-Myc Protein Levels and Reduce Prostate Cancer Cell Growth Investigators report the anti-cancer activity of the macrocyclic peptides [D-Trp]CJ-15,208 (cyclo[Phe-D-Pro-Phe-D-Trp]) and the natural product CJ-15,208 (cyclo[Phe-D-Pro-Phe-Trp]). [Cancer Biol Ther] Abstract | |
| |
REVIEWSConnexins, Important Players in the Dissemination of Prostate Cancer Cells The authors focus on the impact of connexins and gap junctional intercellular communication during the development of prostate cancer, from the primary growth mainly localized in acinar glands and ducts to the distant metastasis mainly concentrated in bone. [Biochim Biophys Acta] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSOwlstone Medical announced the initiation of the PAN Cancer Trial for Early Detection of Cancer in Breath. The large scale clinical study will evaluate the use of Owlstone Medical’s Breath Biopsy® platform for the early detection of multiple cancer types. [Owlstone Medical] Press Release Phase II Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement OncBioMune Pharmaceuticals, Inc. announced that the protocol for the planned Phase II trial of ProscaVax for treatment-naïve prostate cancer patients is awaiting approval from the Institutional Review Board at the host hospital, a preeminent North-Eastern U.S. cancer research network. [OncBioMune Pharmaceuticals, Inc. (Nasdaq. Inc)] Press Release | |
| |
POLICY NEWSMarketing of Unproven Stem Cell-Based Interventions: A Call to Action Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. The authors suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments. [Sci Transl Med] Abstract | Editorial US Lawmakers Seek $1.1 Billion Boost for the NIH The US National Institutes of Health (NIH) would see its budget rise by US$1.1 billion in 2018, to $35.2 billion, under a spending proposal released today by lawmakers in the House of Representatives. [Nature News] Editorial In a Rare Move, FDA Reverses Course on Drug Developed by CEO with Ties to Trump The Food and Drug Administration has changed its tune on an experimental drug for a deadly rare disease, withdrawing a request that the company developing it run another clinical trial. The unusual move comes after President Trump met with the company’s CEO — and promised to speed up what he called a “slow and burdensome” process for drug approvals. [STAT News] Editorial White House’s Dwindling Science Office Leaves Major Research Programs in Limbo US President Donald Trump has pledged to shrink the federal government, and he seems to be starting with science. Nearly six months after taking office, Trump has not chosen a science adviser, and the White House’s Office of Science and Technology Policy has dwindled from around 130 staff members under former president Barack Obama to 35. [Nature News] Editorial
| |
EVENTSNEW 11th International Conference on Cancer Stem Cells Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Computational Biologist – Prostate Cancer (Cancer Research UK Manchester Institute) Postdoctoral Scholar Position – Prostate Cancer (Case Western Reserve University) Academic Position – TRP Channels Screening in Prostate Cancer (Universita’ degli Studi di Torino) Postdoctoral Position – Prostate Cancer (Cleveland Clinic) Postdoctoral Position – Prostate Related Diseases (Baylor College of Medicine) Postdoctoral Fellow – Functional Cancer Genomics (Institute of Oncology Research) Postdoctoral Fellow – Epigenetics and Epigenomics (Cleveland Clinic Lerner Research Institute) Postdoctoral Fellows – Cancer Research (Institute of Oncology Research) Postdoctoral Fellow – Prostate Cancer and Head & Neck Cancer (University of Maryland) Assistant Member – Prostate Cancer (Fred Hutchinson Cancer Research Center) Postdoctoral Fellow – Drug Discovery (The Vancouver Prostate Centre) Research Associate – Prostate Cancer (Meharry Medical College) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|